ELISA-Based Crossmatching Allowing the Detection of Emerging Donor-Specific Anti-HLA Antibodies through the Use of Stored Donors’ Cell Lysates

Table 1

Results of Luminex-based anti-HLA antibody specification analyses and corresponding outcomes of the AMS-crossmatch ELISA for the 42-year-old lung recipient highlighting an involvement of anti-HLA DSA (anti-HLA-B7).

Serum sample	Luminex (Single Donor/ID) Ab specificities	PRA (%)	AMS-ELISA-CM
			Class I	Class II
08/2012	Class I: anti-A9 (23, 24), anti-B7,	54%	n.d.	n.d.
	anti-B27, anti-B40 (60, 61), anti-B47, and anti-B81
	Class II: neg.	0%
07/2013	Class I: anti-A9 (23, 24), anti-B7,	60%	pos.	neg.
	anti-B27, anti-B40 (60, 61), anti-B47, and anti-B81		(1 : 6)
	Class II: neg.	0%
08/2013	Class I: anti-A9 (23, 24), anti-B7,	58%	pos.	neg.
	anti-B27, anti-B40 (60, 61), anti-B47, and anti-B81		(1 : 6)
	Class II: neg.	0%

n.d.: not done; neg.: negative; pos.: positive; antibody specification as prerequisite for entering the waiting list; antibody analyses at the date of the rejection episode; antibody analyses after three apheresis cycles; bold lettering: donor-specific antibodies as detected by virtual (Luminex) or de facto (AMS-ELISA) crossmatching at the highest dilution (parentheses).